GSK’s newly acquired ROS1 inhibitor zidesamtinib (branded Jideytro) won FDA approval for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after prior ROS1 kinase inhibitor therapy. The clearance came roughly a week after GSK closed its $10.6 billion acquisition of Nuvalent. Regulators granted the fast path supported by breakthrough therapy and orphan drug designations, enabling a decision ahead of a scheduled deadline. The approval positions Jideytro as a next-generation option in an already crowded ROS1 portfolio, where prior drugs have had mixed commercial momentum. For deal economics, the early regulatory win reduces “time-to-value” risk for GSK’s acquisition strategy and provides a near-term revenue trigger tied to oncology scale-up and launch execution.